Ocugen has initiated a phase 3 clinical trial of its dry eye disease treatment OCU310, the company announced in a press release.
OCU310 (brimonidine tartrate 0.2%), an investigational twice-daily, steroid-free, preservative- free eye drop, is formulated with OcuNanoE, Ocugen’s proprietary nanoemulsion technology, the release said.
“We believe OCU310 could be an important treatment option for the management of DED, based on brimonidine’s multiple modes of action, our OcuNanoE formulation technology and the favorable results of our recent phase 2 study,” Daniel Jorgensen,
Uncategorized